{"nctId":"NCT00819052","briefTitle":"Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients","startDateStruct":{"date":"2008-12"},"conditions":["HIV Infections"],"count":445,"armGroups":[{"label":"NVP IR","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Nevirapine XR","Drug: Nevirapine IR"]},{"label":"NVP XR","type":"EXPERIMENTAL","interventionNames":["Drug: Nevirapine XR"]}],"interventions":[{"name":"Nevirapine XR","otherNames":[]},{"name":"Nevirapine XR","otherNames":[]},{"name":"Nevirapine IR","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\nHIV infected subjects treated with a Viramune based regimen.\n\nA subject that meets the following inclusion criteria will be eligible for participation in this study:\n\n1. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation.\n2. HIV-1 infected males or females of at least 18 years.\n3. Treatment with Viramune regimen for at least the preceding 18 weeks.\n4. Background therapy with lamivudine/ abacavir(3TC/ABC) (Kivexa® in EU; Epzicom in US), emtricitabine/tenofovir( FTC/TDF) (Truvada) or lamivudine/zidovudine 3TC/AZT (Combivir®).\n5. An HIV viral load \\< 50 copies/mL in preceding 3 months.\n6. An HIV viral load of \\< 50 copies/mL at screening (Visit 1).\n7. Acceptable screening laboratory values that indicate adequate baseline organ function with the following exceptions: alanine aminotrnasferase (ALT) and asparatate aminotransferase (AST) \\< 2.5 × upper limit of normal (ULN) Division of Acquired Immunodeficiency Syndrome (DAIDS Grade 1).\n8. Willingness to abstain from ingesting medications that are listed as contraindicated in the Summary of Product Characteristics (SPC) or package insert (or PI) or Investigator's Brochure during the study.\n9. Karnofsky performance score of \\< 70\n\nExclusion criteria:\n\nSubjects who meet one or more of the following criteria will be excluded from the study:\n\n1. Current treatment with an HIV protease inhibitor\n2. Participation in another trial or use of an investigational medicine within two months prior to Day 1 of this study\n3. Female patients of child-bearing potential who:\n\n   1. Have a positive serum pregnancy test at screening.\n   2. Are breast feeding.\n   3. Are planning to become pregnant\n   4. Are not willing to use a double-barrier methods (simultaneous use of two different methods such as diaphragm with spermicidal substance and condom) of contraception, or require ethinyl estradiol administration. Barrier methods of contraception include diaphragm with spermicidal substance, condom for females, cervical caps and condoms..\n4. Laboratory parameters \\> DAIDS grade 2 Coagulation prothrombin time (PT), partial thromboplastin time (PTT), International Normalized ratio (INR) Hematology (absolute platelets, white blood cells (WBC), absolute neutrophil count, hemoglobin) Biochemistry (total bilirubin, amylase, serum creatinine, fasting glucose, lactate, alkaline phosphatase)\n5. Laboratory parameters \\> DAIDS grade 3 Total triglycerides (total cholesterol no restriction)\n6. Hypersensitivity to any ingredients of the test products\n7. Active drug abuse or chronic alcoholism.\n8. Hepatic cirrhosis stage Child-Pugh B or C\n9. History of severe or acute illness within 60 days prior to Day 1, malignancy or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the trial\n10. Inability to comply with protocol requirements","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Comparison of Virologic Response at Week 24 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population","description":"Primary endpoint was the number of patients with a sustained virologic response through week 24","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"137","spread":null},{"groupId":"OG001","value":"276","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 400 Copies/mL, Full Analysis Set Population","description":"Endpoint was the number of patients with a sustained virologic response through week 2","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"148","spread":null},{"groupId":"OG001","value":"292","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 400 Copies/mL, Full Analysis Set Population","description":"Endpoint was the number of patients with a sustained virologic response through week 4","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"291","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 400 Copies/mL, Full Analysis Set Population","description":"Endpoint was the number of patients with a sustained virologic response through week 8","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"290","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 400 Copies/mL, Full Analysis Set Population","description":"Endpoint was the number of patients with a sustained virologic response through week 12","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"289","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 400 Copies/mL, Full Analysis Set Population","description":"Endpoint was the number of patients with a sustained virologic response through week 24","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":null},{"groupId":"OG001","value":"285","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimates of the Proportions of Patients Without Loss of Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0.986","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.993","spread":null},{"groupId":"OG001","value":"0.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.973","spread":null},{"groupId":"OG001","value":"0.973","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.959","spread":null},{"groupId":"OG001","value":"0.966","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.946","spread":null},{"groupId":"OG001","value":"0.953","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.946","spread":null},{"groupId":"OG001","value":"0.946","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.946","spread":null},{"groupId":"OG001","value":"0.942","spread":null}]}]}]},{"type":"SECONDARY","title":"Summary of CD4 Count (Cells/Cubic Millimeter) at Baseline, Full Analysis Set Population","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"569.7","spread":"215.6"},{"groupId":"OG001","value":"557.7","spread":"213.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 2, Observed Cases, Full Analysis Set Population","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"115.2"},{"groupId":"OG001","value":"-4.7","spread":"107.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 4, Observed Cases, Full Analysis Set Population","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"110.8"},{"groupId":"OG001","value":"-15.4","spread":"114.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 8, Observed Cases, Full Analysis Set Population","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.6","spread":"122.9"},{"groupId":"OG001","value":"-24.4","spread":"117.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 12, Observed Cases, Full Analysis Set Population","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.3","spread":"152.9"},{"groupId":"OG001","value":"-10.2","spread":"118.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 24, Observed Cases, Full Analysis Set Population","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.4","spread":"162.8"},{"groupId":"OG001","value":"45.7","spread":"137.6"}]}]}]},{"type":"SECONDARY","title":"Comparison of CD4 Count (Cells/Cubic Millimeter) Change From Baseline at Week 24, Observed Cases, Full Analysis Set Population","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.74","spread":"12.7072"},{"groupId":"OG001","value":"46.10","spread":"9.2053"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population","description":"Endpoint was the number of patients with a sustained virologic response through week 48","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"268","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population","description":"Endpoint was the number of patients with a sustained virologic response through week 60","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"122","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"253","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population","description":"Endpoint was the number of patients with a sustained virologic response through week 72","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"265","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population","description":"Endpoint was the number of patients with a sustained virologic response through week 84","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"244","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population","description":"Endpoint was the number of patients with a sustained virologic response through week 96","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"242","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population","description":"Endpoint was the number of patients with a sustained virologic response through week 108","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"119","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"247","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population","description":"Endpoint was the number of patients with a sustained virologic response through week 120","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"235","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population","description":"Endpoint was the number of patients with a sustained virologic response through week 132","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"238","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population","description":"Endpoint was the number of patients with a sustained virologic response through week 144","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"238","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population","description":"Endpoint was the number of patients with a sustained virologic response at their last available visit","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"261","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 48, Observed Cases, Full Analysis Set Population","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","spread":"142.8"},{"groupId":"OG001","value":"139.8","spread":"126.9"},{"groupId":"OG002","value":"52.7","spread":"143.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 60, Observed Cases, Full Analysis Set Population","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1","spread":"138.1"},{"groupId":"OG001","value":"11.5","spread":"138.4"},{"groupId":"OG002","value":"55.1","spread":"136.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 72, Observed Cases, Full Analysis Set Population","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.3","spread":"128.6"},{"groupId":"OG001","value":"77.9","spread":"109.5"},{"groupId":"OG002","value":"67.4","spread":"141.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 84, Observed Cases, Full Analysis Set Population","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.3","spread":"156.5"},{"groupId":"OG001","value":"134.6","spread":"214.2"},{"groupId":"OG002","value":"55.0","spread":"130.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 96, Observed Cases, Full Analysis Set Population","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.1","spread":"156.7"},{"groupId":"OG001","value":"55.4","spread":"80.7"},{"groupId":"OG002","value":"60.2","spread":"130.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 108, Observed Cases, Full Analysis Set Population","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.4","spread":"160.4"},{"groupId":"OG001","value":"117.4","spread":"151.3"},{"groupId":"OG002","value":"73.5","spread":"151.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 120, Observed Cases, Full Analysis Set Population","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.5","spread":"168.4"},{"groupId":"OG001","value":"90.0","spread":"151.0"},{"groupId":"OG002","value":"66.6","spread":"182.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 132, Observed Cases, Full Analysis Set Population","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.8","spread":"153.6"},{"groupId":"OG001","value":"124.8","spread":"158.7"},{"groupId":"OG002","value":"70.8","spread":"146.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 144, Observed Cases, Full Analysis Set Population","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.3","spread":"151.6"},{"groupId":"OG001","value":"205.6","spread":"388.6"},{"groupId":"OG002","value":"82.7","spread":"157.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Last Available Visit, Observed Cases, Full Analysis Set Population","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.9","spread":"157.1"},{"groupId":"OG001","value":"165.9","spread":"302.5"},{"groupId":"OG002","value":"80.9","spread":"163.5"}]}]}]},{"type":"SECONDARY","title":"Proportion of Virologic Response (Viral Load <400 Copies/mL) Trough Week 144","description":"Endpoint was the number of patients with a sustained virologic response through week 144","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"250","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in VL (HIV-1 Viral Load) at Each Visit","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.4","spread":"536.9"},{"groupId":"OG001","value":"58.4","spread":"202.3"},{"groupId":"OG002","value":"-4.3","spread":"67.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11004.4","spread":"125415"},{"groupId":"OG001","value":"94.1","spread":"218.5"},{"groupId":"OG002","value":"-1.8","spread":"69.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1747.0","spread":"19806"},{"groupId":"OG001","value":"0.0","spread":"0.0"},{"groupId":"OG002","value":"-4.9","spread":"68.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2798.8","spread":"31301"},{"groupId":"OG001","value":"4.1","spread":"11.7"},{"groupId":"OG002","value":"4140.1","spread":"67801"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"17.7"},{"groupId":"OG001","value":"0.0","spread":"0.0"},{"groupId":"OG002","value":"168.4","spread":"1974.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.1","spread":"574.2"},{"groupId":"OG001","value":"0.0","spread":"0.0"},{"groupId":"OG002","value":"-3.5","spread":"70.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"42.7"},{"groupId":"OG001","value":"0.4","spread":"1.1"},{"groupId":"OG002","value":"-2.3","spread":"71.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":"78.7"},{"groupId":"OG001","value":"4.0","spread":"10.6"},{"groupId":"OG002","value":"-1.8","spread":"79.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"24.5"},{"groupId":"OG001","value":"0.0","spread":"0.0"},{"groupId":"OG002","value":"-4.6","spread":"70.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4472.6","spread":"36357"},{"groupId":"OG001","value":"86.4","spread":"211.0"},{"groupId":"OG002","value":"4103.2","spread":"66822"}]}]}]},{"type":"SECONDARY","title":"Changes in Safety Parameters Related to Treatment","description":"Occurence of investigations related to treatment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Occurence of Rashes","description":"drug-related rashes by severity","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Occurence of Hepatic Events","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"New AIDS or AIDS-related Progression Event or Death","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Loss of Virologic Response","description":"Kaplan-Meier Estimates of time to loss of virologic response defined as the time between the start of treatment and the time of treatment failure, up to and including the time when the last patient was on treatment for 48 weeks.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"393","spread":null},{"groupId":"OG001","value":"391","spread":null}]}]}]},{"type":"SECONDARY","title":"Genotypic Resistance Associated With Virologic Failure","description":"Genotypic resistance associated with virologic failure.\n\nThis endpoint was not analysed due to lack of data.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Trough Plasma Concentration","description":"Trough plasma concentrations of Nevirapine at steady state after multiple oral administrations of Nevirapine treatments from day 1 (visit 2) to week 48 (visit 9).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3720","spread":"65.4"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3650","spread":"38.1"},{"groupId":"OG001","value":"3270","spread":"57.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3720","spread":"36.6"},{"groupId":"OG001","value":"3230","spread":"49.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4080","spread":"38.2"},{"groupId":"OG001","value":"3650","spread":"46.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4170","spread":"41.1"},{"groupId":"OG001","value":"3590","spread":"50.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4080","spread":"36.9"},{"groupId":"OG001","value":"3750","spread":"41.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4370","spread":"40.6"},{"groupId":"OG001","value":"3930","spread":"41.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3960","spread":"41.8"},{"groupId":"OG001","value":"3650","spread":"45.0"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":33,"n":148},"commonTop":["Nasopharyngitis","Diarrhoea","Bronchitis","Back pain","Upper respiratory tract infection"]}}}